8-K filing — Zoetis Inc. (ZTS)

Zoetis Q3 2026 Earnings Call Transcript

Zoetis (NYSE:ZTS) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs. For

Zoetis Exec Says Growth In Online And In-Store Retail Channels Has Slowed From 2025 Levels; Dermatology Price Decline In Quarter Was Entirely Driven By Gross-To-Net Investments, Not List-Price Cuts; International Companion-animal Sales Were Hurt By Dermatology Pressure In Developed European Markets

Zoetis Executive Says Q3 Canine Vet Visits Declined ~5%, With Itch-Related Visits Down ~3%; Volume Declines From Generic Convenia And Cerenia Competition Moderated To Lowest Level Since Those Generics Entered Market In Q1

Zoetis Exec Says New U.S. Dermatology Competitor Has Had Limited Share Gains Due To Supply Challenges; Expects Third-To-/Fourth Quarter Revenue Decline In High Single-Digit Range, Partly Due To Third-quarter Promotional Activity

Zoetis Reports Third Quarter 2026 Financial Results

Zoetis announced its third-quarter 2026 financial results, highlighting portfolio growth in livestock and diagnostics while narrowing revenue guidance and raising adjusted EPS guidance for the full year.

Zoetis Adjusts Short-Term Financial Guidance

Zoetis has updated its short-term financial targets, adjusting its outlook to reflect current business conditions.